On March 26, 2026, Pinnacle Medicines proudly announced the successful completion of its Series B funding round, securing an impressive $89 million with significant oversubscription. This pivotal financing initiative was jointly spearheaded by LAV and Foresite Capital, and saw active participation from Quan Capital, H Kang Capital, RA Capital Management, Logos Capital, as well as existing investors OrbiMed and Qiming Venture Partners. As a pioneering biotechnology firm, Pinnacle Medicines leverages a cutting-edge, proprietary AI-integrated physical simulation technology platform to pioneer the development of oral peptide therapeutics. The infusion of these funds will fuel the progression of projects targeting autoimmune and cardiovascular-metabolic diseases into the clinical phase, bolster the expansion of the peptide research and development platform, and fortify overall R&D capabilities.